Protagonist Therapeutics (PTGX)
Discovers peptide medicines and earns collaboration economics from partnered ICOTYDE and rusfertide.
$145.65
vs last close+0.67 (+0.47%)
Something off on this page? Send us feedback.
13F · 13D/G · Form 4
| Institutions | 118.03% | 76.38M shares | |
|---|---|---|---|
| 358 holders · as of Jun 30, 2026 | |||
| Insiders | 1.59% | 1.03M shares | |
| 9 holders · as of Sep 10, 2026 | |||
| Adds to | 119.62% | ||
64.71M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 119.62%; nothing is left for Other.
13F, as of Jun 30, 2026
358 holders · 76.38M shares · 62 new positions · 204 increased · 91 reduced · 39 closed
| Holder | Shares | % outstanding | Chg q/q | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 10.31M | 15.93% | +528.5K | Aug 7, 2026 |
| Farallon Capital Management LLC | 6.35M | 9.81% | 0 | Aug 14, 2026 |
| RTW Investments, LP | 5.06M | 7.82% | +2.1K | Aug 14, 2026 |
| Vanguard Portfolio Management LLC | 3.63M | 5.61% | +148.1K | Aug 13, 2026 |
| Wellington Management Group LLP | 3.42M | 5.28% | −182.9K | Aug 14, 2026 |
| UBS Group AG | 3.40M | 5.25% | −1.78M | Aug 13, 2026 |
| State Street Corp | 3.32M | 5.13% | +204.8K | Aug 7, 2026 |
| Vanguard Capital Management LLC | 2.85M | 4.41% | +47.5K | Aug 13, 2026 |
13D/G · 5% or more, as filed
| Holder | % of class | Shares | Form | Filed |
|---|---|---|---|---|
| BlackRock, Inc. | 13.80% | 8.58M | 13G | Oct 17, 2025 |
| RTW Investments, LP | 8.10% | 5.06M | 13G | Feb 17, 2026 |
| Vanguard Portfolio Management | 5.53% | 3.53M | 13G | Apr 29, 2026 |
| State Street Corporation | 5.40% | 3.18M | Oct 16, 2024 | |
| Wellington Management Group LLP | 5.10% | 3.17M | 13G | Feb 10, 2026 |
| Vanguard Capital Management | 5.09% | 3.25M | 13G | Apr 30, 2026 |
Form 4
Latest trades
| Date | Insider | Type | Shares | Avg price | Owned after |
|---|---|---|---|---|---|
| Sep 10, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 7,278 | $144.10 | 522,968 |
| Sep 9, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 63,548 | $146.18 | 522,968 |
| Sep 8, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 54,174 | $145.87 | 522,968 |
| Aug 11, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 34,239 | $148.52 | 523,478 |
| Aug 10, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 65,761 | $149.11 | 523,478 |
| Jun 23, 2026 | William D. Waddilldirector | Sale | 9,000 | $117.94 | 7,825 |
| Jun 10, 2026 | William D. Waddilldirector | Sale | 9,000 | $107.68 | 7,825 |
| May 29, 2026 | William D. Waddilldirector | Sale | 9,000 | $99.64 | 7,825 |
| May 12, 2026 | Dinesh V. Ph D. Pateldirector, officer: President and CEO | Sale | 75,000 | $100.12 | 523,478 |
| May 8, 2026 | Bryan Giraudodirector | Sale · 2 lots | 11,130 | $100.00 | 12,695 |
House and Senate disclosures
Not reported.